Lori Freedman Purchases 100,863 Shares of Organogenesis Holdings Inc. (NASDAQ:ORGO) Stock

Organogenesis Holdings Inc. (NASDAQ:ORGO - Get Free Report) insider Lori Freedman purchased 100,863 shares of the firm's stock in a transaction that occurred on Wednesday, June 4th. The stock was purchased at an average price of $2.82 per share, with a total value of $284,433.66. Following the purchase, the insider now directly owns 695,058 shares of the company's stock, valued at $1,960,063.56. The trade was a 16.97% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Lori Freedman also recently made the following trade(s):

• On Friday, June 6th, Lori Freedman acquired 9,022 shares of Organogenesis stock. The stock was purchased at an average cost of $2.99 per share, for a total transaction of $26,975.78.
• On Thursday, June 5th, Lori Freedman acquired 142,379 shares of Organogenesis stock. The shares were purchased at an average cost of $2.91 per share, with a total value of $414,322.89.

Organogenesis Stock Up 13.5%

Shares of NASDAQ ORGO traded up $0.41 during midday trading on Monday, hitting $3.44. 2,247,351 shares of the company's stock were exchanged, compared to its average volume of 1,150,852. The firm's fifty day simple moving average is $3.82 and its 200-day simple moving average is $3.85. The company has a market cap of $436.38 million, a PE ratio of -57.33 and a beta of 1.63. Organogenesis Holdings Inc. has a twelve month low of $2.28 and a twelve month high of $6.71. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.09 and a quick ratio of 2.74.

Organogenesis (NASDAQ:ORGO - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.17). Organogenesis had a negative net margin of 1.62% and a negative return on equity of 2.69%. The company had revenue of $86.69 million during the quarter, compared to analysts' expectations of $90.77 million. Research analysts predict that Organogenesis Holdings Inc. will post -0.07 EPS for the current fiscal year.

Institutional Investors Weigh In On Organogenesis

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Wells Fargo & Company MN raised its stake in Organogenesis by 29.6% during the 4th quarter. Wells Fargo & Company MN now owns 41,471 shares of the company's stock worth $133,000 after acquiring an additional 9,464 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Organogenesis by 18.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,789,265 shares of the company's stock valued at $8,925,000 after purchasing an additional 442,772 shares during the last quarter. Prudential Financial Inc. lifted its holdings in shares of Organogenesis by 92.9% in the 4th quarter. Prudential Financial Inc. now owns 237,720 shares of the company's stock valued at $761,000 after purchasing an additional 114,500 shares during the last quarter. Squarepoint Ops LLC lifted its holdings in shares of Organogenesis by 53.2% in the 4th quarter. Squarepoint Ops LLC now owns 126,791 shares of the company's stock valued at $406,000 after purchasing an additional 44,051 shares during the last quarter. Finally, Mackenzie Financial Corp lifted its holdings in shares of Organogenesis by 255.1% in the 4th quarter. Mackenzie Financial Corp now owns 76,353 shares of the company's stock valued at $244,000 after purchasing an additional 54,850 shares during the last quarter. 49.57% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Morgan Stanley increased their target price on Organogenesis from $4.00 to $6.00 and gave the company an "equal weight" rating in a report on Wednesday, March 5th.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.